PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC12188416::ACT019239

tyroserleutide

Evidence text

Paper-level observation

In the YSL (8 mg/kg) + 5F–C12 (0.8 mg/kg) group, tumor inhibition increased markedly, reaching approximately 65.7% (Table S2).
textConfidence: medium

Assay observation

Activity
Anticancer
Subtype
Antibacterial
Measure
percent_inhibition
Comparator
=
Raw observation
approximately 65.7%
Normalized measurement
=65.7%
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
MCF-7
Assay method
Not reported by source
Sequence
YSL
Standardization
ready simple

Source publication

Artificial Tyroserleutide Transporters for Synergistic Cancer Therapy.

JACS Au · 2025

DOI 10.1021/jacsau.5c00204 PMC12188416
Parent mention Integrated peptide

Related peptide identities

PEPDIA-PLP-004213PEPDIA-INT-025613

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.